Blueprint Medicines Corporation (NASDAQ:BPMC) – Analysts at Jefferies Group cut their Q3 2017 earnings estimates for Blueprint Medicines Corporation in a research report issued on Wednesday. Jefferies Group analyst C. Augustine now expects that the biotechnology company will post earnings per share of ($0.92) for the quarter, down from their prior forecast of ($0.78). Jefferies Group currently has a “Buy” rating and a $52.00 target price on the stock. Jefferies Group also issued estimates for Blueprint Medicines Corporation’s Q4 2017 earnings at ($0.98) EPS, FY2017 earnings at ($3.61) EPS, FY2018 earnings at ($4.08) EPS, FY2019 earnings at ($4.44) EPS, FY2020 earnings at ($4.51) EPS and FY2021 earnings at ($2.14) EPS.

Blueprint Medicines Corporation (NASDAQ:BPMC) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.75) by $0.11. Blueprint Medicines Corporation had a negative return on equity of 45.58% and a negative net margin of 388.91%. The company had revenue of $5.89 million for the quarter, compared to the consensus estimate of $5.96 million. During the same period last year, the firm posted ($0.70) EPS. The company’s revenue was down 16.7% compared to the same quarter last year.

TRADEMARK VIOLATION NOTICE: This piece was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/05/q3-2017-eps-estimates-for-blueprint-medicines-corporation-decreased-by-jefferies-group-bpmc.html.

Several other research analysts have also recently weighed in on the company. Zacks Investment Research cut Blueprint Medicines Corporation from a “hold” rating to a “sell” rating in a research report on Friday. Canaccord Genuity set a $56.00 price objective on Blueprint Medicines Corporation and gave the stock a “buy” rating in a research report on Wednesday. BidaskClub upgraded Blueprint Medicines Corporation from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 27th. Cowen and Company reiterated a “buy” rating on shares of Blueprint Medicines Corporation in a research report on Tuesday, June 6th. Finally, Wedbush reiterated an “outperform” rating and set a $55.00 price objective on shares of Blueprint Medicines Corporation in a research report on Tuesday, June 6th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Blueprint Medicines Corporation presently has an average rating of “Buy” and a consensus price target of $47.90.

Shares of Blueprint Medicines Corporation (NASDAQ BPMC) opened at 48.66 on Friday. The firm’s market cap is $1.62 billion. The firm’s 50-day moving average is $50.35 and its 200-day moving average is $41.89. Blueprint Medicines Corporation has a 1-year low of $20.69 and a 1-year high of $56.81.

Several hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC boosted its position in shares of Blueprint Medicines Corporation by 23.3% in the second quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock worth $208,000 after buying an additional 778 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Blueprint Medicines Corporation by 4,457.0% in the second quarter. BNP Paribas Arbitrage SA now owns 4,238 shares of the biotechnology company’s stock worth $215,000 after buying an additional 4,145 shares during the last quarter. Verde Servicos Internacionais S.A. bought a new position in shares of Blueprint Medicines Corporation during the first quarter worth approximately $199,000. UBS Asset Management Americas Inc. bought a new position in shares of Blueprint Medicines Corporation during the first quarter worth approximately $201,000. Finally, Trexquant Investment LP bought a new position in shares of Blueprint Medicines Corporation during the first quarter worth approximately $230,000. Institutional investors own 88.72% of the company’s stock.

In related news, CEO Jeffrey W. Albers sold 20,000 shares of the firm’s stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $50.47, for a total value of $1,009,400.00. Following the transaction, the chief executive officer now owns 47,920 shares in the company, valued at $2,418,522.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kate Haviland sold 6,357 shares of the firm’s stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $50.00, for a total value of $317,850.00. Following the completion of the transaction, the insider now owns 6,357 shares in the company, valued at approximately $317,850. The disclosure for this sale can be found here. Insiders have sold a total of 73,622 shares of company stock worth $3,771,405 in the last quarter. Company insiders own 3.40% of the company’s stock.

Blueprint Medicines Corporation Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Earnings History and Estimates for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.